1. Clinical Overview
Fluorometholone (0.1% w/w) is a potent, medium-strength synthetic glucocorticoid (corticosteroid) formulated for topical ophthalmic use. It is a fluorinated derivative of prednisolone, designed to provide anti-inflammatory, anti-allergic, and anti-proliferative effects on the ocular surface and anterior segment of the eye. Its fluorination enhances its lipophilicity, allowing for better corneal penetration compared to some non-fluorinated steroids, while its esterification (typically as acetate) contributes to its potency. It is a mainstay in Indian ophthalmology for managing a variety of inflammatory and allergic conditions, offering a favorable balance between efficacy and a relatively lower propensity to raise intraocular pressure (IOP) compared to more potent steroids like dexamethasone or prednisolone acetate, though it is not devoid of this risk.
| Onset | Duration | Bioavailability |
|---|---|---|
| Clinical improvement in symptoms like redness and itching is typically observed within 24 to 48 hours. Peak anti-inflammatory effect is achieved within several days of consistent use. | The duration of action is approximately 6 to 8 hours per instillation, necessitating multiple daily doses (e.g., 2-4 times daily) for continuous therapeutic effect. | Topical ophthalmic bioavailability is low systemically (<5%). However, local ocular bioavailability (corneal and intraocular penetration) is significant due to its lipophilic nature, especially when formulated as Fluorometholone Acetate. |
2. Mechanism of Action
Fluorometholone binds to cytoplasmic glucocorticoid receptors (GR) in target ocular cells (conjunctival, corneal, and anterior uveal tissues). The drug-receptor complex translocates to the nucleus, where it modulates gene transcription. It induces the synthesis of anti-inflammatory proteins (lipocortins) while inhibiting the transcription of genes encoding for pro-inflammatory mediators such as phospholipase A2, cyclooxygenase-2 (COX-2), various cytokines (IL-1, IL-2, IL-6, TNF-α), and adhesion molecules. This results in stabilization of lysosomal membranes, inhibition of leukocyte migration, and suppression of capillary dilation and permeability.
3. Indications & Uses
- Inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe (e.g., Allergic Conjunctivitis, Vernal Keratoconjunctivitis)
- Steroid-responsive inflammatory conditions of the eye (e.g., Episcleritis, Scleritis)
- Post-operative inflammation following ophthalmic surgery (e.g., cataract surgery)
4. Dosage & Administration
Adult Dosage: One drop into the conjunctival sac of the affected eye(s) 2 to 4 times daily. In severe inflammation, dosing may be initiated every 1-2 hours during waking hours, then tapered. Do not discontinue abruptly; taper frequency over 7-14 days.
Administration: 1. Wash hands. 2. Tilt head back. 3. Gently pull lower eyelid down to form a pouch. 4. Instill prescribed number of drops without touching the dropper tip to eye, fingers, or any surface. 5. Close eyes gently for 1-2 minutes, applying gentle pressure to the nasolacrimal duct (inner corner of eye) to minimize systemic absorption. 6. Wait at least 5-10 minutes before instilling any other eye medication.
5. Side Effects
Common side effects may include:
- Transient Ocular Stinging/Burning upon instillation
- Blurred Vision temporarily after application
- Watery Eyes
- Mild Ocular Discomfort
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Other Ocular Corticosteroids | Additive risk of IOP elevation, cataract, and infection. | Major |
| Acetazolamide, Dorzolamide, Timolol (Antiglaucoma drugs) | Fluorometholone may counteract IOP-lowering effect, requiring dose adjustment. | Moderate |
| Cyclosporine (ophthalmic) | Potential additive immunosuppression; may be used together under supervision for specific conditions. | Moderate |
| NSAIDs (e.g., Ketorolac tromethamine eye drops) | Increased risk of corneal adverse events (ulceration, perforation), especially post-surgery. | Major |
| Systemic CYP3A4 Inducers (e.g., Rifampicin, Phenytoin, Carbamazepine) | May increase metabolism of systemically absorbed fluorometholone, potentially reducing efficacy. | Minor |
7. Patient Counselling
- DO wash hands before use.
- DO apply gentle pressure on the inner corner of the eye (nasolacrimal duct) for 1-2 minutes after instillation.
- DO wait at least 5-10 minutes before using other eye drops.
- DO keep the bottle tip clean and avoid touching it.
- DO NOT discontinue the medication abruptly without consulting your doctor; a taper schedule may be needed.
- DO NOT wear contact lenses while using this medication unless approved by your doctor.
- DO NOT share your eye drops with anyone.
8. Toxicology & Storage
Overdose: Topical overdose is unlikely to cause acute systemic toxicity. Symptoms from excessive topical use include severe ocular hypertension, glaucoma, cataract, and increased risk of infection. Accidental oral ingestion may cause systemic corticosteroid effects: Cushingoid symptoms, hyperglycemia, adrenal suppression, GI upset.
Storage: Store at room temperature (15°C to 25°C). Protect from light. Do not freeze. Keep the bottle tightly closed when not in use. Keep out of reach of children. Discard the bottle 28 days after first opening. Do not use if the solution is discolored or contains particles.